Hu-rhEGF-rP64k/Mont cancer vaccine can induces a neutralizing antibody-mediated immune response, against the normal circulating self-protein antigen Epidermal Growth Factor (EGF), which is the main ligand of the Epidermal Growth Factor Receptor (EGF-R). This evidence concerns the gene EGFR and cancer.